Phaseline

Companies › Actio Biosciences

Actio Biosciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABS-1230
KCNT1 inhibitor
Ion channelsPhase 2KCNT1-Related EpilepsyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07156201ABS-1230Phase 1KCNT1-Related EpilepsyNeurologyDec 2026
NCT07600736ABS-1230Phase 2KCNT1-Related EpilepsyNeurologyJan 2027

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

Biossil Xenon Pharmaceuticals Dasher Neuroscience ThromBio Appello Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.